SCHEDULE 13G/A: ARK Investment Management and Cathie Wood Disclose 11.87% Stake in 10x Genomics

ARK Investment Management LLC and its CEO, Catherine D. Wood, have jointly disclosed a significant beneficial ownership stake of 11.87% in 10x Genomics, Inc.'s Class A Common Stock.

Summary

• ARK Investment Management LLC and Catherine D. Wood have filed an Amendment No. 1 to their Schedule 13G, disclosing their beneficial ownership in 10x Genomics, Inc.
• As of March 31, 2025, the aggregate amount beneficially owned by both reporting persons is 12,845,713 shares of Class A Common Stock.
• This ownership represents 11.87% of the Class A Common Stock outstanding.
• ARK Investment Management LLC holds sole voting power over 12,038,996 shares and shared voting power over 287,876 shares, with sole dispositive power over 12,845,713 shares.
• Catherine D. Wood holds shared voting power over 12,326,872 shares and shared dispositive power over 12,845,713 shares.
• The filing confirms that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of 10x Genomics, Inc.
• ARK Innovation ETF, a series of a Delaware statutory trust, is noted as a client of ARK Investment Management LLC with an interest in the securities exceeding 5 percent.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. A significant stake by a well-known investment firm like ARK and Catherine D. Wood can be viewed as a vote of confidence in the company, although the filing itself is purely factual and regulatory.

Positives

• The disclosure of a significant stake by a prominent investment firm like ARK Investment Management and Catherine D. Wood may signal confidence in 10x Genomics' future prospects.
• The filing explicitly states that the securities are held in the ordinary course of business, indicating a long-term investment strategy rather than an activist intent.

Risks

• The concentration of a significant portion of the company's Class A Common Stock in the hands of a single investment manager and its principal could lead to increased volatility if ARK were to significantly alter its position.
• While the filing states no intent to influence control, a large beneficial ownership stake inherently carries potential influence over corporate decisions.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding 10x Genomics, Inc.'s future performance or strategic direction. It is solely a disclosure of beneficial ownership.

Industry Context

This filing indicates continued investment interest from a prominent asset manager known for its focus on disruptive innovation, particularly in the genomics and biotechnology sectors. ARK's significant stake in 10x Genomics aligns with its investment thesis in companies at the forefront of genomic research and technology, suggesting a belief in the long-term growth potential of the industry and 10x Genomics' position within it.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional holding may influence investor perception and potentially stock price, signaling institutional confidence. It also clarifies the ownership structure.
• Company Management: Awareness of a large, non-activist institutional holder may influence strategic considerations, though the filing explicitly states no intent to influence control.

Key Dates

Keywords

10x Genomics, ARK Investment Management, Catherine D. Wood, Schedule 13G, Beneficial Ownership, Class A Common Stock, Investment Management, Biotechnology, Genomics, SEC Filing